Opendata, web and dolomites

BeVision SIGNED

Better vision after cataract and refractive surgery with photonics technology

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BeVision project word cloud

Explore the words cloud of the BeVision project. It provides you a very rough idea of what is the project "BeVision" about.

validate    market    introduction    assembled    36    clinically    profit    refractive    track    protocols    select    suffer    simulator    operation    fast    outcome    commercialisation    medical    actual    population    outcomes    half    cataract    patients    visual    voptica    surgeries    aberrations    ophthalmic    business    objectively    correcting    rapid    prepare    skills    clinical    as    eye    vision    world    2025    commercial    record    revenue    cataracts    6m    age    simulate    lenses    helping    satisfied    optimisation    correct    cumulative    laser    patient    subsequently    intraocular    bevision    people    dramatically       benefit    figure    eyesight    understand    solid    disrupt    optics    solutions    institutes    doctor    200    disruptive    innovation    generating    vao    clouding    older    billion    4m    65    imperfections    competitive    forehand    solution    post    interoperable    optical    effect    adaptive    validation    successful    ophthalmology    million    aging    swiftly    refine    manufactures    surgery    lens    device    software   

Project "BeVision" data sheet

The following table provides information about the project.

Coordinator
VOPTICA S.L. 

Organization address
address: CAMPUS DE ESPINARDO, CTRA. MADRID KM.388, PARQUE CIENTIFICO DE MURCIA. EDIFICIO T. LOCALES T1/3 Y T2/9
city: MURCIA
postcode: 30100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.voptica.com
 Total cost 2˙486˙788 €
 EC max contribution 1˙740˙751 € (70%)
 Programme 1. H2020-EU.3.1.4. (Active ageing and self-management of health)
2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.1.6. (Health care provision and integrated care)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2020-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VOPTICA S.L. ES (MURCIA) coordinator 1˙740˙751.00

Map

 Project objective

As we get older, we all will develop eyesight problems. Around the age of 65 more than half of us suffer from eye lens clouding, or cataracts. Cataract surgery is now the most common operation in Europe, with 4.3 million people getting treated each year, a figure that will only increase due to our fast aging population. However, 200,000 of them are not satisfied with the outcome of their eye correcting surgeries as they can’t experience on forehand what their vision will be. Voptica has developed the Visual Adaptive Optics (VAO) simulator, a disruptive innovation in eye testing, allowing patients to experience the effect of intraocular lenses or laser surgery on their vision before the actual operation, helping the patient and doctor to select their best solution and understand what their vision will be like post-surgery.

Our technology is used by world-leading research institutes and lens-manufactures, but to prepare VAO for clinical market introduction our project BeVision will refine its software protocols, make it interoperable and clinically validate the technology. After a successful clinical validation, VAO will be the only medical device in the world that can measure objectively all eye aberrations of patients and, subsequently, simulate the different optical solutions to correct the patient’s eye imperfections during visual testing. Our technology will dramatically improve the outcomes of cataract and laser refractive surgeries.

Our highly competitive technology can swiftly disrupt the $4.4 billion ophthalmology device market, generating a rapid business growth for Voptica, with a cumulative revenue of € 36.4m and a profit of € 8.6m by 2025.

To make BeVision a commercial success, we have assembled a consortium with a solid track record in the development, optimisation, clinical validation and commercialisation of ophthalmic devices and have all the skills and resources for its commercial exploitation to benefit our business and Europe.

 Deliverables

List of deliverables.
WP4 Scientific publications Documents, reports 2020-03-09 16:07:04

Take a look to the deliverables list in detail:  detailed list of BeVision deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BEVISION" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BEVISION" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.4.;H2020-EU.2.1.1.;H2020-EU.2.3.1.;H2020-EU.3.1.6.)

CLINICOVERY (2018)

CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical research

Read More  

SensUS (2018)

SensUS: A non-invasive and quantitative ultrasound (QUS) device for an objective monitoring of the childbirth labour process.

Read More  

ImmuneHunter (2017)

Bioinformatics platform for profiling of health: allowing early and accurate detection of multiple diseases simultaneously

Read More